experimental melanoma

Summary

Summary: Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

Top Publications

  1. ncbi Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2
    S K Mendiratta
    Valentis, Inc, The Woodlands, Texas 77381-4248, USA
    Cancer Res 61:859-63. 2001
  2. ncbi Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
  3. ncbi Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor
    Daisuke Umeda
    Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 812 8581, Japan
    J Biol Chem 283:3050-8. 2008
  4. ncbi Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21
    Jacqueline D Shields
    Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland
    Science 328:749-52. 2010
  5. ncbi Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice
    Halina Was
    Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Gronostajowa 7, 30 387 Krakow, Poland
    Am J Pathol 169:2181-98. 2006
  6. ncbi Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis
    Ralf J Ludwig
    Department of Dermatology, , Frankfurt am Main, Germany
    Cancer Res 64:2743-50. 2004
  7. ncbi CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
  8. ncbi Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute (NCI, National Institute of Health, Bethesda, MD 20892-1502, USA
    J Exp Med 198:569-80. 2003
  9. ncbi Differentially oriented populations of actin filaments generated in lamellipodia collaborate in pushing and pausing at the cell front
    Stefan A Koestler
    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Dr Bohr Gasse 3, 1030, Vienna, Austria
    Nat Cell Biol 10:306-13. 2008
  10. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001

Research Grants

  1. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2007
  2. Electrically Mediated Delivery of Immunostimulatory DNA to Experimental Melanomas
    Loree Heller; Fiscal Year: 2006
  3. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2007
  4. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2007
  5. Migration of Mature and Immature Dendritic Cells
    HENDRIK VAN DEVENTER; Fiscal Year: 2006
  6. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2003
  7. Immunochaperone-based gene therapy targeting prostate cancer
    Xiang yang Wang; Fiscal Year: 2007
  8. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2009
  9. Scavenger Receptor-A and Immune Regulation
    Xiang yang Wang; Fiscal Year: 2007
  10. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2001

Detail Information

Publications201 found, 100 shown here

  1. ncbi Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2
    S K Mendiratta
    Valentis, Inc, The Woodlands, Texas 77381-4248, USA
    Cancer Res 61:859-63. 2001
    ....
  2. ncbi Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  3. ncbi Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor
    Daisuke Umeda
    Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 812 8581, Japan
    J Biol Chem 283:3050-8. 2008
    ..Additionally, we found that eEF1A is up-regulated by EGCG through 67LR. Overall, these findings implicate both eEF1A and MYPT1 in EGCG signaling for cancer prevention through 67LR...
  4. ncbi Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21
    Jacqueline D Shields
    Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland
    Science 328:749-52. 2010
    ..We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression...
  5. ncbi Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice
    Halina Was
    Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Gronostajowa 7, 30 387 Krakow, Poland
    Am J Pathol 169:2181-98. 2006
    ....
  6. ncbi Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis
    Ralf J Ludwig
    Department of Dermatology, , Frankfurt am Main, Germany
    Cancer Res 64:2743-50. 2004
    ..cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.
  7. ncbi CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  8. ncbi Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute (NCI, National Institute of Health, Bethesda, MD 20892-1502, USA
    J Exp Med 198:569-80. 2003
    ....
  9. ncbi Differentially oriented populations of actin filaments generated in lamellipodia collaborate in pushing and pausing at the cell front
    Stefan A Koestler
    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Dr Bohr Gasse 3, 1030, Vienna, Austria
    Nat Cell Biol 10:306-13. 2008
    ....
  10. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001
    ..CONCLUSION: Expression of a single chemokine receptor gene, CCR7, increased B16 cell metastasis to draining lymph nodes, suggesting that cancer cells may co-opt normal mechanisms of lymph node homing during metastasis...
  11. ncbi A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  12. ncbi CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  13. ncbi Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
    ..These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor...
  14. ncbi Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
    P Dematos
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Oncol 68:79-91. 1998
    ....
  15. ncbi Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk
    1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
    Immunol Rev 188:122-35. 2002
    ..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
  16. ncbi Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression
    S J Orlow
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York 10016, USA
    Proc Natl Acad Sci U S A 92:10152-6. 1995
    ....
  17. ncbi The central role of CD4(+) T cells in the antitumor immune response
    K Hung
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Exp Med 188:2357-68. 1998
    ..Cytokines produced by these CD4(+) T cells activate eosinophils as well as macrophages that produce both superoxide and nitric oxide. Both of these cell types then collaborate within the site of tumor challenge to cause its destruction...
  18. ncbi Decreased tumor surveillance in perforin-deficient mice
    M E van den Broek
    Institute of Experimental Immunology, University of Zurich, Switzerland
    J Exp Med 184:1781-90. 1996
    ....
  19. ncbi Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
    R P Sutmuller
    Department of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    J Exp Med 194:823-32. 2001
    ..Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity...
  20. ncbi Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies
    Anna Katharina Simon
    MRC Human Immunology Unit and Nuffield Department of Medicine, Institute of Molecular Medicine, OX3 9DS, Oxford, United Kingdom
    Cancer Cell 2:315-22. 2002
    ..We show that protected mice recognize melanocyte differentiation self-antigens. Importantly, tumor immunity is mediated by antibodies, as it can be transferred by serum from protected mice...
  21. ncbi IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma
    Hak Ling Ma
    Wyeth Research, Cambridge, MA 02140, USA
    J Immunol 171:608-15. 2003
    ..We conclude that IL-21 immunotherapy warrants clinical evaluation as a potential treatment for cancer...
  22. ncbi Angiogenesis, lymphangiogenesis, and melanoma metastasis
    Michael Streit
    Berlex Biosciences, Richmond, CA 94804, USA
    Oncogene 22:3172-9. 2003
    ..These observations have important implications for prognosis and treatment of human melanomas...
  23. ncbi Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis
    Juan A Recio
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Cancer Res 62:6724-30. 2002
    ....
  24. ncbi TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2004-13. 2003
    ..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
  25. ncbi Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma
    Romina S Goldszmid
    Instituto Leloir, , Argentina
    J Immunol 171:5940-7. 2003
    ..Therefore, DCs loaded with cells undergoing apoptotic death can prime melanoma-specific helper and CTLs and provide long term protection against a poorly immunogenic tumor in mice...
  26. ncbi Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis
    Maria I Harrell
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Department of Comparative Medicine, University of Washington, 1100 Fairview Ave N, MS C2 023, P O Box 19024, Seattle, WA 98109, USA
    Am J Pathol 170:774-86. 2007
    ..Lymph node lymphangiogenesis and increased lymph flow through tumor-draining lymph nodes may actively promote metastasis via the lymphatics...
  27. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
    ..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
  28. ncbi Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression
    A F Tilkin-Mariame
    INSERM U563 CPTP, Département Innovation thérapeutique et Oncologie Moléculaire, Toulouse, France
    FASEB J 19:1513-5. 2005
    ..These observations indicate that protein geranylgeranylation as well as Rho protein are critical for costimulatory and IFN-gamma-dependent MHC class I molecule expression in melanoma...
  29. ncbi In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity
    Fumiyoshi Okano
    Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    J Immunol 174:2645-52. 2005
    ..These findings demonstrate that unmodified tumor-associated self Ags can be targeted to DCs in vivo to induce potent systemic antitumor immunity...
  30. ncbi Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma
    Baocun Sun
    Department of Pathology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin 300060, PR China
    Cancer Lett 249:188-97. 2007
    ..Hypoxia can enhance tumor cell invasion and metastasis. The cause and the molecular mechanism are still not clear...
  31. ncbi Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo
    Yanyan Lou
    Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:6783-90. 2004
    ..Collectively, these findings illuminate a new potential application for DCs in the in vivo stimulation of adoptively transferred T cells and may be a useful approach for the immunotherapy of cancer...
  32. ncbi Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity
    Xin-Yuan Chen
    Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, 22 Hankou Road, Nanjing 210093, China
    Clin Cancer Res 12:5834-40. 2006
    ..This may provide with a novel treatment for metastatic tumors. Moreover, we have established a convenient method to evoke specific CTL against tumor angiogenesis...
  33. ncbi Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes
    Kristian M Hargadon
    Department of Microbiology and Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 177:6081-90. 2006
    ..Thus, activated T cells lacking effector function develop through incomplete differentiation in the lymph nodes of late-stage tumor-bearing mice, rather than through suppression of previously differentiated cells...
  34. ncbi Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  35. ncbi Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
    Katsuyoshi Furumoto
    Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA
    J Clin Invest 113:774-83. 2004
    ....
  36. ncbi IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  37. ncbi Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
    Tianhong Wang
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nat Med 10:48-54. 2004
    ..We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system...
  38. ncbi Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation
    Uta B Hofmann
    Department of Dermatology, Julius Maximilian s University, Wurzburg, Germany
    Cancer Res 63:8221-5. 2003
    ....
  39. ncbi The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model
    Baocun Sun
    Department of Pathology, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 300060, People s Republic of China
    J Cancer Res Clin Oncol 133:979-85. 2007
    ..To investigate the influence of different microenvironments on tumor microcirculation patterns and invasiveness capability...
  40. ncbi Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy
    H Winter
    Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, OR 97213, USA
    J Immunol 166:7370-80. 2001
    ..These results indicate that in this adoptive immunotherapy model, neither a direct effect on the tumor nor an indirect effect of IFN-gamma through activation of myeloid or lymphoid cells is critical for therapeutic efficacy...
  41. ncbi The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma
    H Haghnegahdar
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Leukoc Biol 67:53-62. 2000
    ..These data suggest that continuous expression of MGSA/GRO proteins may facilitate tumor growth by stimulating the growth of microvessels into the tumor (paracrine) and by affecting melanocyte growth (autocrine)...
  42. ncbi Engagement of the OX-40 receptor in vivo enhances antitumor immunity
    A D Weinberg
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 164:2160-9. 2000
    ....
  43. ncbi Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model
    C Wack
    Department of Toxicology, , Versbacher Strasse 9, , Germany
    Melanoma Res 11:247-53. 2001
    ..In conclusion, we have established a model system that seems to be appropriate for both the optimization of this therapeutic regimen and the characterization of effector mechanisms...
  44. ncbi High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction
    Andrew G Brandmaier
    Department of Surgery, Indiana University School of Medicine, and the Walther Oncology Center, Indianapolis, IN 46202, USA
    J Immunother 32:677-88. 2009
    ..These findings suggest that high-avidity CD4+ T cells can overcome endogenous conditions and mediate their antitumor effects exclusively through the elicitation of CD8+ T cell immunity...
  45. ncbi CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
    C A Chambers
    University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Annu Rev Immunol 19:565-94. 2001
    ..This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy...
  46. ncbi Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells
    Michael Y Gerner
    Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 182:2726-37. 2009
    ..These results show that TIDC are functionally distinct from normal interstitial DC, thus indicating that neoplastic tissues can evade effector CD4 T cells through modification of DC competence...
  47. ncbi Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
    M Bellone
    Laboratory of Tumor Immunology, Cancer Immunotherapy and Gene Therapy Program, H San Raffaele Scientific Institute, Milan, Italy
    J Immunol 165:2651-6. 2000
    ..Our results strongly emphasize the relevance of the tumor Ag in the definition of immunotherapeutic strategies for cancer, and support the use of peptide-pulsed DC as cancer vaccine in humans...
  48. ncbi Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
    B Seliger
    Johannes Gutenberg Universitat, III Medizinische Klinik, Mainz, Germany
    Cancer Res 61:1095-9. 2001
    ....
  49. ncbi Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model
    S Cubillos
    Laboratorio de Fisiopatologia, Instituto Venezolano de Investigaciones Cientificas (IVIC, Caracas, Venezuela
    Anticancer Res 17:2207-11. 1997
    ..The results suggest that the reduction in the number of metastases may be related to the effect of blocking TNF activity...
  50. ncbi Subcellular localization of myosin-V in the B16 melanoma cells, a wild-type cell line for the dilute gene
    A A Nascimento
    Department of Morphology, Faculdade de Medicina de Ribeirao Preto Universidade de Sao Paulo, Brazil
    Mol Biol Cell 8:1971-88. 1997
    ....
  51. ncbi B16 as a mouse model for human melanoma
    W W Overwijk
    National Cancer Institute, NIH, Bethesda, Maryland, USA
    Curr Protoc Immunol . 2001
    ..Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns...
  52. ncbi Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice
    Y C Wang
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Eur J Immunol 25:1163-7. 1995
    ..In summary, our study demonstrated that HSA can provide a co-stimulatory signal for the T cell immune response against tumor cells in a murine model...
  53. ncbi The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia
    T Stradal
    Institute of Molecular Biology, Austrian Academy of Sciences, 5020, Salzburg, Austria
    Curr Biol 11:891-5. 2001
    ..Our findings are the first to suggest a direct involvement of members of the Abi protein family in the control of actin polymerization in protrusion events, and establish the Abi proteins as potential regulators of motility...
  54. ncbi 7th Jan Waldenström Lecture. The biology of human cancer metastasis
    I J Fidler
    Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston
    Acta Oncol 30:668-75. 1991
    ..These data suggest that systemic physiological signals can be usurped by neoplastic cells. Collectively, the factors that regulate metastasis are the intrinsic properties of metastatic cells and host factors involved in homeostasis...
  55. ncbi Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma
    Gecioni Loch Neckel
    Laboratório de Farmacotécnica, Departamento de Ciencias Farmaceuticas, Universidade Federal de Santa Catarina, Brazil
    J Pharm Pharmacol 59:1359-64. 2007
    ..This assumption was supported by the in-vitro study, in which both PLA and 49 kDa PLA-PEG nanocapsules containing CPT were more cytotoxic than the free drug against B16-F10 melanoma cells...
  56. ncbi A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model
    Jennifer A McWilliams
    Department of Pharmacology, 3M Pharmaceuticals, St. Paul, MN 55144, USA
    J Immunol 177:155-61. 2006
    ..However, consistent with most clinical data, simple generation of higher affinity T cells is insufficient to mediate tumor immunity...
  57. ncbi An attempt to isolate genes responsible for spontaneous and experimental metastasis in the mouse model
    A Ito
    Department of Pathology, Osaka University Medical School, Suita, Japan
    Histol Histopathol 17:951-9. 2002
    ..Moreover, similar roles were expected for the genes in the process by which human melanoma cells metastasize...
  58. ncbi Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth
    K Takeda
    Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan
    Cell Immunol 214:194-200. 2001
    ..These results suggested a substantial role of TRAIL as the effector molecule that eliminates subcutaneously developing TRAIL-sensitive tumors...
  59. ncbi Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid
    Jie Zhao
    Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University, Nanjing, PR China
    Eur J Pharmacol 589:127-31. 2008
    ..Thus we concluded for the first time that gambogic acid could inhibit the adhesion and migration of B16-F10 cells in vitro and in vivo, in which down-regulation of alpha(4) integrin expression was involved...
  60. ncbi Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice
    Chengwen Liu
    Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1165-75. 2008
    ..Our data thus demonstrated that activated pDCs are capable of initiating effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of NK cells, cDCs, and CD8(+) T cells...
  61. ncbi Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue
    Manuela Banciu
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Neoplasia 10:108-17. 2008
    ..One of the major inhibitory actions of LCL-PLP on tumor growth is the reduction of the TAM-mediated production of pro-angiogenic factors, whereas production of anti-angiogenic factors by these cells is hardly affected...
  62. ncbi Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
    J M Kaplan
    Genzyme Corporation, Genzyme Molecular Oncology, Framingham, MA 01701, USA
    J Immunol 163:699-707. 1999
    ..Taken together, these results support the concept of cancer immunotherapy using DCs transduced with Ad vectors encoding tumor-associated Ags...
  63. ncbi A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase
    K Tsukamoto
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    EMBO J 11:519-26. 1992
    ..We now report that TRP-2 (tyrosinase related protein-2), which maps to and is mutated at the slaty locus in mice, encodes a protein with DOPAchrome tautomerase activity...
  64. ncbi IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb
    Daisuke Kamimura
    Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan
    J Immunol 177:306-14. 2006
    ..These results demonstrated IL-2-enhancing effects of the anti-IL-2 mAb in vivo and suggest that combining a neutralizing anti-IL-2 Ab with IL-2 gene delivery might be used effectively to enhance IL-2 functions in clinical applications...
  65. ncbi Antitumor activity of IFN-lambda in murine tumor models
    Atsuko Sato
    Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Shimotsuke, Tochigi, Japan
    J Immunol 176:7686-94. 2006
    ..These findings suggested that local delivery of IFN-lambda might prove a useful adjunctive strategy in the clinical treatment of human malignancies...
  66. ncbi Antiangiogenic and antitumor activities of IL-27
    Motomu Shimizu
    Medical R and D Center, Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Organization for Medical Research, Honkomagome, Bunkyo ku, Japan
    J Immunol 176:7317-24. 2006
    ..These results suggest that IL-27 possesses potent antiangiogenic activity, which plays an important role in its antitumor and antimetastatic activities...
  67. ncbi Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice
    V Terraube
    INSERM U143, , France
    J Thromb Haemost 4:519-26. 2006
    ..CONCLUSION: These findings suggest that VWF plays a protective role against tumor cell dissemination in vivo. Underlying mechanisms remain to be investigated...
  68. ncbi [Antitumor effect of gene gun-mediated DNA vaccine pWRG-neu immunization in C57BL/6 mice]
    Yuan-yuan Zha
    National Laboratory of Molecular Oncology, Cancer Institute (Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 25:320-4. 2003
    ..CONCLUSION: Gene gun-mediated gene transfer is effective and practicable. DNA vaccine pWRG-neu is potent in preventing subsequent tumor cells challenge, inhibiting the tumor growth and metastasis...
  69. ncbi GM-CSF-surface-modified B16.F10 melanoma cell vaccine
    Jimin Gao
    Institute of Molecular Immunology, College of Biotechnology, Southern Medical University, 1838 Guangzhou Dadao Bei, Guangzhou, Guangdong 510515, China
    Vaccine 24:5265-8. 2006
    ..F10 whole tumor cell vaccine could induce strong and long-lasting systemic protection against the wild-type tumor challenge. Therefore, the platform may represent a fast, efficient and safe approach for the whole tumor cell vaccination...
  70. ncbi [Inhibitory effect of tripeptide compound tyroservaltide on invasion and metastasis of mouse melanoma cell line B16-F10]
    Xu-Chun Che
    Department of Immunology, Tianjin Medical University, Tianjin 300070, P. R. China
    Ai Zheng 25:275-80. 2006
    ..21%. The expression of ICAM-1 in lung tissue was lower in YSV group than in normal saline group. CONCLUSION: YSV can inhibit the growth, invasion, and metastasis of B16-F10 cells...
  71. ncbi [Taohong Siwu decoction II inhibits the angiogenesis and the expressions of VEGF and KDR/FLK-1 in C57BL/6J mice bearing B16 melanoma]
    Shu-Mei Wang
    College of Traditional Chinese Medicine of Chongqing University of Medical sciences, China
    Zhongguo Zhong Yao Za Zhi 30:1866-9. 2005
    ....
  72. ncbi Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice
    C Rossi
    Consorzio Mario Negri Sud, Santa Maria Imbaro (CH, Italy
    J Thromb Haemost 4:608-13. 2006
    ..05). Lung colonies were 74.2-72.6% reduced by MCM09 (10 mg kg(-1)) given 60 or 120 min before cells, but not by MCM09 given 60 min thereafter, suggesting a direct cell interaction as a mechanism underlying antitumor activity...
  73. ncbi Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells
    Mohammed Amarzguioui
    The Biotechnology Centre of Oslo, Norway
    Clin Cancer Res 12:4055-61. 2006
    ....
  74. ncbi Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 3:205-11. 2006
    ..Therefore, DC-derived EXO may represent a more effective EXO-based vaccine in induction of antitumor immunity...
  75. ncbi Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis
    Kaimeng Hu
    Research Center of Developmental Biology and Department of Histology and Embryology, Second Military Medical University, Shanghai 200433, PR China
    Immunol Lett 113:19-28. 2007
    ....
  76. ncbi Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell
    Zhi Yao
    The College of Pharmaceuticals and Biotechnology, Tianjin University, Tianjin, China
    Mol Med 13:14-21. 2007
    ..31%. By analyses with Western blot and real-time RT-PCR, we found that YSL markedly inhibited the expression of ICAM-1 in B16-F10 cells. These data suggest that YSL inhibits the growth, invasion, and adhesion of B16-F10 cells...
  77. ncbi Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells
    Huaining Teng
    Institute of Biochemistry and Cell Biology, Model Organism Research Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Acta Biochim Biophys Sin (Shanghai) 39:278-84. 2007
    ..These results widen the clinical application of the microencapsulated cell endostatin delivery system in cancer treatment...
  78. ncbi Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals
    Maria Jose Herrero
    Gene Therapy Group, Department of Pharmacology, Faculty of Medicine, University of Valencia, Av Blasco Ibanez 15, 46010 Valencia, Spain
    Ann N Y Acad Sci 1091:412-24. 2006
    ....
  79. ncbi Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice
    Mónica Bequet-Romero
    Recombinant Antibodies Laboratory, Cancer Research Department, Center for Genetic Engineering and Biotechnology, Cubanacan, Playa, P O Box 6162, Havana 10600, Cuba
    Angiogenesis 10:23-34. 2007
    ..Our results indicate that human VEGF DNA can be employed for anti-angiogenic active immunotherapy in mice, and that direct cell cytotoxicity is a contributor mechanism to the overall anti-tumor effects seen in immunized animals...
  80. ncbi Effect of amentoflavone on the inhibition of pulmonary metastasis induced by B16F-10 melanoma cells in C57BL/6 mice
    C Guruvayoorappan
    Amala Cancer Research Centre, Amala Nagar, Thrissur, Kerala, India
    Integr Cancer Ther 6:185-97. 2007
    ....
  81. ncbi Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine
    Huili Wang
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China
    Cancer Lett 268:129-36. 2008
    ..Rituximab-coated tumor cell vaccine also expanded the clinical Rituximab applications...
  82. ncbi Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects
    Jeffrey S Moyer
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109 1904, USA
    Biol Blood Marrow Transplant 12:1010-9. 2006
    ..In addition, DC vaccinations did not appear to exacerbate graft-versus-host disease. These experiments support the feasibility of DC vaccine strategies in the setting of allogeneic BMT...
  83. ncbi Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity
    Gabriela R Rossi
    Tumor Immunology Section, NewLink Genetics Corporation, ISU Research Park 2901 South Loop Drive, Ames, IA 50010, USA
    J Immunother 31:545-54. 2008
    ..This study established the safety and efficacy data of allogeneic alphaGal whole cell vaccines and constituted the basis for the initiation of human clinical trials to treat human malignancies...
  84. ncbi CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection
    Changwan Hong
    School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
    J Immunol 177:6747-57. 2006
    ..Immunization resulted in an NKT cell-dependent antitumor adaptive immune response, which was associated with both CD4+ T cells and cytokine IFN-gamma...
  85. ncbi Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis
    Amnon Hoffman
    Department of Pharmaceutics, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Med Chem 51:1406-14. 2008
    ..Finally, 84% of the intravenously administered cis-ACCP to rats was excreted intact in the urine...
  86. ncbi Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo
    Honghai Zhang
    Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200433, People's Republic of China
    Cell Stress Chaperones 11:216-26. 2006
    ..Furthermore, we found that immunization with multiple Hsp70 fusion proteins resulted in a better anti-tumor effect...
  87. ncbi Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo
    R Stojkovic
    Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka, Zagreb, Croatia
    Methods Find Exp Clin Pharmacol 28:347-54. 2006
    ..e., on day 7, 9, 11, 13, and 15 after transplantation of tumor cells...
  88. ncbi Activity of bacteriophages in murine tumor models depends on the route of phage administration
    Krystyna Dabrowska
    Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
    Oncol Res 15:183-7. 2005
    ..The role of the route of bacteriophage administration should be considered in the context of the effectiveness and safety of such therapies...
  89. ncbi CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  90. ncbi Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses
    Jun Lu
    Department of Immunology and Cancer Center, Mayo College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 172:4575-82. 2004
    ....
  91. ncbi Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses
    Mark J Dobrzanski
    Trudeau Institute, Saranac Lake, NY 12983, USA
    J Immunol 172:1380-90. 2004
    ..Collectively, Tc1 and Tc2 effector cell immunotherapy mediate long-term tumor immunity by different mechanisms that subsequently potentiate endogenous recipient-derived type 1 antitumor responses...
  92. ncbi A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases
    Sylvie Froidevaux
    Laboratory of Endocrinology, Department of Research, University Hospital and University Children s Hospital, Basel, Switzerland
    J Nucl Med 45:116-23. 2004
    ..The aim of this study was to develop a positron emitter-labeled alpha-MSH analog suitable for PET imaging of melanoma metastases...
  93. ncbi A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number
    Bela Szende
    1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Molecular Pathology Research Group of Hungarian Academy of Sciences, Budapest, Hungary
    In Vivo 16:281-6. 2002
    ....
  94. ncbi Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity
    Stephen M Todryk
    Division of Oncology, St George s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK
    Cancer Immunol Immunother 53:323-30. 2004
    ..Thus, while heating of vaccine cells in some models is highly beneficial, and is a means of enhancing immunogenicity without genetic modification or inclusion of potentially toxic adjuvants, additional immune enhancement may be required...
  95. ncbi Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity
    Anke S Lonsdorf
    Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    J Immunol 171:3941-6. 2003
    ..The data show that intratumor injection of CpG-oligodeoxynucleotides is a promising strategy for rendering tumors immunogenic...
  96. ncbi Antitumor and antimetastatic activity of IL-23
    Chia Hui Lo
    Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    J Immunol 171:600-7. 2003
    ..The results showed that CD8(+) T cells, but not CD4(+) T cells or NK cells, were crucial for the antitumor activity of IL-23...
  97. ncbi Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin
    Naoko Seki
    Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
    J Immunol 168:3484-92. 2002
    ..Therefore, although granule-mediated killing is of paramount importance for CTL-mediated lysis in vitro, some major in vivo effector mechanisms clearly are independent of perforin...
  98. ncbi Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine
    S Yei
    Division of Cancer, The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA
    Gene Ther 9:1302-11. 2002
    ..F10 melanoma more effectively than analogous vaccines containing only secreted GM-CSF. These data warrant further development and clinical testing of mbGM-CSF tumor cell vaccines...
  99. ncbi Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice
    Yung Choon Yoo
    Department of Microbiology, College of Medicine, Konyang University, Nonsan, Chungnam, Korea
    Arch Pharm Res 25:522-7. 2002
    ....
  100. ncbi Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response
    Christiane Wack
    Department of Toxicology, , Versbacher Strasse 9, , Germany
    Cancer Immunol Immunother 51:431-9. 2002
    ..Together, these findings demonstrate the ability of DTIC/DNCB treatment to induce an effective T cell-dependent host immune response against a syngeneic tumor...
  101. ncbi Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells
    Yuji Tada
    Division of Pathology, Chiba Cancer Center Research Institute, Graduate School of Medicine, Chiba University, Japan
    J Immunol 169:2241-5. 2002
    ..These results identify a novel role for FasL in augmenting tumor-DC interactions and subsequent tumor Ag acquisition by DCs, and suggest that FasL-expressing tumor cells could be used to generate tumor-specific DC vaccines...

Research Grants118 found, 100 shown here

  1. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2007
    ..CTCL is addressed in one Project and one Pilot Study, and SCC in one Pilot Study. This endeavor represents the synergistic integration of well-established individual research programs towards our collective goals. ..
  2. Electrically Mediated Delivery of Immunostimulatory DNA to Experimental Melanomas
    Loree Heller; Fiscal Year: 2006
    ....
  3. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2007
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  4. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2007
    ..cells, will be activated by Toll-like receptor triggering and then used to vaccinate mice bearing either experimental melanoma or spontaneous mammary carcinoma metastases...
  5. Migration of Mature and Immature Dendritic Cells
    HENDRIK VAN DEVENTER; Fiscal Year: 2006
    ..All have extensive experience in developing the careers o f young scientists. This work has the support of the Lineberger Comprehensive Cancer Center which has made accessible its core facilities. ..
  6. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2003
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  7. Immunochaperone-based gene therapy targeting prostate cancer
    Xiang yang Wang; Fiscal Year: 2007
    ..The proposed research could lead to the design of a clinical trial for patients with prostate cancer in the very near future. ..
  8. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2009
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  9. Scavenger Receptor-A and Immune Regulation
    Xiang yang Wang; Fiscal Year: 2007
    ..Further, successful testing of SR-A-silenced dendritic cells as a vaccine to break tolerance against tumor- associated self-antigens will provide a novel immunotherapeutic approach targeting the inhibitory innate receptor. ..
  10. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2001
    ..abstract_text> ..
  11. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2007
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  12. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2000
    ..The quantitative dosimetric information resulting from this research is urgently needed for risk assessment and guidance of sonographers, and for developing the full therapeutic potential of medical ultrasound. ..
  13. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert M Prins; Fiscal Year: 2010
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  14. Subharmonic Microbubble Signals for Pressure Estimation
    Flemming Forsberg; Fiscal Year: 2007
    ..This will allow potentially life-threatening diseases, such as increased pressure in the liver, to be diagnosed early. ..
  15. A tyrosinase-targeted drug design for the treatment of melanoma
    Majid Moridani; Fiscal Year: 2007
    ..In this work we will be developing novel phenol based drugs for treatment of melanoma. ..
  16. Contrast-Enhanced Ultrasound Detection of Angiogenesis
    Flemming Forsberg; Fiscal Year: 2004
    ..If successful, this project will permit non-invasive ultrasound evaluations of anti-angiogenic tumor therapies in animals as well as humans. ..
  17. Immune targeting of melanoma-associated antigens in glioma
    Robert Prins; Fiscal Year: 2007
    ..World renowned scientists and technology in many disciplines will serve to enhance the ability of Dr. Prins to accomplish the goals set forth in this application. ..
  18. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2007
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  19. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2009
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  20. Quantitative Subharmonic Breast Imaging
    Flemming Forsberg; Fiscal Year: 2010
    ....
  21. SYNTHESIS AND EVALUATION OF NOVEL PHOSPHORAMIDATES
    RICHARD BORCH; Fiscal Year: 1999
    ..The ultimate goal is to exploit the unique properties of phosphoramidate chemistry to develop new drugs with reduced host toxicity and increased efficacy against resistant poorly responsive tumors. ..
  22. DNA-based Vaccine for Treatment of Oral Carcinoma
    Edward Cohen; Fiscal Year: 2006
    ..It is expected that development of an effective vaccine to be used alone or in combination with conventional therapy will expand the future therapeutic options available for patients with oral cancer. ..
  23. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary J Akhurst; Fiscal Year: 2010
    ..assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  24. Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1
    Mohamed Khan; Fiscal Year: 2004
    ..Chest CT and Chest x-ray will be taken to record tumor response, and to compare with 99mTc-MIBI scans. ..
  25. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    ....
  26. Molecular mechanisms of choroidal neovascularization and vascular homeostasis
    ALEXANDER GEORG MARNEROS; Fiscal Year: 2010
    ..These findings are likely to reveal novel molecular targets for the treatment of neovascular age-related macular degeneration. ..
  27. CELL/CELL COMMUNICATION DURING MELANOMA PROGRESSION
    Meenhard Herlyn; Fiscal Year: 2000
    ..This proposal addresses the biological significance of inter-cellular signaling during distinct steps of melanoma tumor progression. ..
  28. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2007
    ....
  29. Applying nanosecond pulse electric fields to treat skin cancer
    RICHARD LEE NUCCITELLI; Fiscal Year: 2010
    ..This promises to become a scar-free therapy that could replace surgery and improve the quality of life for hundreds of thousands of dermatology patients treated for skin cancer each year. ..
  30. Cell-Cell Communication During Melanoma Development
    Meenhard Herlyn; Fiscal Year: 2009
    ..These studies will demonstrate how dysregulation of homeostasis results in tumor formation and targeting subpopulations of malignant cells leads to successful therapy. ..
  31. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  32. The Etiology of UV-Induced Melanoma
    David Mitchell; Fiscal Year: 2007
    ..From these studies we hope to define the effective solar wavelength boundaries of melanoma, identify the class of DNA damage critical to CMM and elucidate the role of DNA repair in tumor suppression. ..
  33. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2003
    ..Our unique in vitro/in vivo models are suitable to investigate etiology, early detection, and prevention of human melanoma. ..
  34. CELL CELL COMMUNICATION DURING MELANOMA DEVELOPMENT
    Meenhard Herlyn; Fiscal Year: 2004
    ..As additional signaling pathways are being defined, therapeutic strategies that would mimic the regulatory control of keratinocytes over E-cadherin-expressing melanoma cell will be developed as a long-term objective. ..